TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In a phase IIb trial involving adults with type 2 diabetes and overweight or obesity, the highest tested dose of eloralintide plus tirzepatide was associated with 23.3% weight loss over 48 weeks, compared with 14.8% with tirzepatide alone. The combination group also had more adverse-event-related treatment discontinuations. Eli Lilly plans to move the combination into phase III development by the end of the year.
A phase IIb trial in adults with type 2 diabetes and overweight or obesity found that the highest tested dose of investigational eloralintide plus tirzepatide was associated with 23.3% body-weight loss over 48 weeks, compared with 14.8% among participants taking tirzepatide alone. The results, presented at the European Association for the Study of Diabetes annual meeting in Milan, also showed more treatment discontinuations because of adverse events in the combination group.
The 10-arm, double-blind study randomized 367 adults in the United States and Argentina to placebo, eloralintide alone, tirzepatide alone, several dose combinations, or a group that began tirzepatide and added eloralintide at week 24. The reported weight-loss figures use the trial’s efficacy estimand, a method for analyzing outcomes under specified assumptions about treatment and missing data.
At the highest combination dose, 25% of participants lost at least 30% of their body weight, compared with 12% in the tirzepatide-alone group. The study presenter, Liana Billings, MD, MMSc, of Endeavor Health, also reported that 96% in both groups reached an HbA1c below 7%, a commonly used blood-sugar target. HbA1c below 5.7% was reached by 77% in the highest-dose combination group and 66% with tirzepatide alone.
Tolerability differed between the groups. Treatment-emergent adverse events were reported in 84% of the highest-dose combination group, versus 71.4% with tirzepatide alone. Discontinuation because of adverse events occurred in 27% and 2.9%, respectively. One participant in a lower-dose combination group died; investigators judged the death unrelated to the study drug, according to the report.
Weight Loss and Treatment Trade-Offs
The findings suggest that pairing drugs acting on different hormone pathways may produce greater weight loss for some people with type 2 diabetes than tirzepatide alone. That possibility matters because weight management and blood-sugar control are linked concerns in this population, and people with diabetes have historically lost less weight on GLP-1-based medicines than people without diabetes.
However, the weight-loss result is not enough to establish that the combination should be used in clinical care. The higher rate of adverse-event-related discontinuation is a substantial counterpoint: a treatment’s potential benefit must be weighed against whether patients can tolerate and continue it. These are results from a mid-stage trial, not evidence of an approved combination or a definitive comparison across all patients and doses.
Popular right now
Ninja CREAMi 7-in-1 Ice Cream Maker, NC299AMZ
De'Longhi Rivelia Automatic Espresso Machine with Milk Frother
Samsung 85-Inch QN70H Neo QLED 4K Smart TV (2026)
As an affiliate, we earn on qualifying purchases.
How the Two Drugs Work
Eloralintide is an investigational selective amylin receptor agonist. Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, acts on GIP and GLP-1 receptors. The combination is intended to target three hormone pathways involved in appetite and blood-sugar regulation: GIP, GLP-1 and amylin.
During this study the medicines were given as two separate injections. Billings said plans were underway to develop a single-injection formulation. Eloralintide is also being studied on its own in phase III trials for obesity. The combination trial’s 48-week results were presented at the EASD meeting; the source report says Eli Lilly plans to advance the combination into phase III by the end of the year.
Questions Before Larger Trials
The reported results do not establish whether the weight-loss difference will persist beyond 48 weeks, how the combination will perform in a larger phase III population, or which patients are most likely to benefit. The trial had 367 participants divided among 10 groups, so individual arms were smaller than the total enrollment. The source report does not provide detailed breakdowns of specific adverse events or explain the causes of the higher discontinuation rate.
The findings were presented at a medical meeting, and the combination remains investigational. It is not yet clear what doses or patient groups would be tested in phase III, whether a single-injection version will be ready for those studies, or how regulators might assess the balance between added weight loss and tolerability.
Phase III Plans and Further Evidence
Eli Lilly plans to begin phase III development of the combination by the end of the year, according to the source report. Those studies will need to test the findings in larger groups and provide more information about longer-term weight change, blood-sugar outcomes, safety and treatment discontinuation.
Further reports may also clarify the intended doses and whether the two medicines can be delivered in a single injection. Until later-stage evidence and regulatory review are available, the phase IIb results should be understood as promising trial findings with a notable tolerability concern, not as a change in current treatment guidance.
Key Questions
What did the trial find about weight loss?
Over 48 weeks, participants assigned to the highest tested dose of eloralintide plus tirzepatide lost 23.3% of body weight in the efficacy analysis, compared with 14.8% among those assigned to tirzepatide alone.
Did the combination improve blood-sugar measures?
The presenter reported that 96% in both the highest-dose combination and tirzepatide-alone groups reached an HbA1c below 7%. An HbA1c below 5.7% was reported in 77% of the combination group and 66% of the tirzepatide-alone group.
What safety or tolerability concern was reported?
Treatment-emergent adverse events occurred in 84% of the highest-dose combination group and 71.4% of the tirzepatide-alone group. Discontinuation because of adverse events was reported in 27% versus 2.9%, respectively.
Is eloralintide plus tirzepatide available as a treatment?
No. The combination is investigational and was studied in a phase IIb trial. Eli Lilly plans to advance it into phase III development, but the source report does not say that it has been approved for use.
Source: rss
